697 related articles for article (PubMed ID: 14613287)
1. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
2. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
3. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
4. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
6. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
[TBL] [Abstract][Full Text] [Related]
8. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.
Sinigaglia L; Nervetti A; Mela Q; Bianchi G; Del Puente A; Di Munno O; Frediani B; Cantatore F; Pellerito R; Bartolone S; La Montagna G; Adami S
J Rheumatol; 2000 Nov; 27(11):2582-9. PubMed ID: 11093437
[TBL] [Abstract][Full Text] [Related]
9. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
10. Calcaneus ultrasonometry and dual-energy X-ray absorptiometry for the evaluation of vertebral fracture risk.
Frediani B; Acciai C; Falsetti P; Baldi F; Filippou G; Siagkri C; Spreafico A; Galeazzi M; Marcolongo R
Calcif Tissue Int; 2006 Oct; 79(4):223-9. PubMed ID: 16969597
[TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
12. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
Angeli A; Guglielmi G; Dovio A; Capelli G; de Feo D; Giannini S; Giorgino R; Moro L; Giustina A
Bone; 2006 Aug; 39(2):253-9. PubMed ID: 16574519
[TBL] [Abstract][Full Text] [Related]
14. Disc space narrowing is associated with an increased vertebral fracture risk in postmenopausal women: the OFELY Study.
Sornay-Rendu E; Munoz F; Duboeuf F; Delmas PD;
J Bone Miner Res; 2004 Dec; 19(12):1994-9. PubMed ID: 15537442
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
16. The relationship between back pain and future vertebral fracture in postmenopausal women.
Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
[TBL] [Abstract][Full Text] [Related]
17. Fracture prediction from bone mineral density in Japanese men and women.
Fujiwara S; Kasagi F; Masunari N; Naito K; Suzuki G; Fukunaga M
J Bone Miner Res; 2003 Aug; 18(8):1547-53. PubMed ID: 12929946
[TBL] [Abstract][Full Text] [Related]
18. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
19. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
